Seizure freedom and reducing the risk of sudden unexpected death in patients with focal epilepsy treated with cenobamate or other antiseizure medications. [PDF]
EpilepsiaSperling MR +3 more
europepmc +1 more source
Emptying the fridge syndrome: a case of nocturnal food craving associated with peak perampanel concentration. [PDF]
Epilepsy Behav RepVassallo P, Sander JW.
europepmc +1 more source
Epilepsy Therapy Screening From 1975 to 2026 and Beyond: Merging Established and New Approaches to Develop Novel Therapies. [PDF]
Epilepsy CurrMetcalf CS +3 more
europepmc +1 more source
Drugs, 2020 Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset seizures in adult patients.
Susan J. Keam (6594447)
openaire +3 more sources
Related searches:
Effects of cenobamate on cognitive performance of epilepsy patients
Seizure: the Journal of the British Epilepsy Association, 2022Cenobamate (CNB) is a new antiseizure medication (ASM) for the treatment of focal epilepsy in adults. While efficacy of CNB was confirmed in controlled clinical trials, its effects on cognition are unclear. Cognitive adverse effects of ASM affect quality of life and retention rate. Therefore, we investigated whether the adjunctive treatment with CNB is
Elisa Schutz +2 more
exaly +4 more sources
Is Cenobamate the Breakthrough We Have Been Wishing for?
International Journal of Molecular Sciences, 2021 Close to one-third of patients with epilepsies are refractory to current anti-seizure medications; however, trials with cenobamate suggest effectiveness in such patients with focal onset seizures.
Nicola Specchio +2 more
exaly +2 more sources
Epilepsia, 2023 Objective: Recent clinical trials have shown that cenobamate substantially improves seizure control in focal-onset drug-resistant epilepsy (DRE). However, little is known about cenobamate's performance in highly active (≥20 seizures/month) and ultra ...
Patrick B Moloney +2 more
exaly +1 more source
Dose Adjustment of Concomitant Antiseizure Medications During Cenobamate Treatment: Expert Opinion Consensus Recommendations [PDF]
Neurology and Therapy, 2022 INTRODUCTION: Our objective was to provide expert consensus recommendations to improve treatment tolerability through dose adjustments of concomitant antiseizure medications (ASMs) during addition of cenobamate to existing ASM therapy in adult patients ...
Michael C Smith +2 more
exaly +2 more sources
Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database
Frontiers in PharmacologyObjective:This study aims to analyze adverse drug events (ADEs) associated with cenobamate from the FAERS database, covering the third quarter of 2020 to the second quarter of 2023.Methods:Data related to cenobamate-associated ADEs from the third quarter
Huiqin Xu, Chen Shihao, Xu Huiqin
exaly +2 more sources
Neurology and TherapyCenobamate has demonstrated efficacy in patients with treatment-resistant epilepsy, including patients who continued to have seizures after epilepsy surgery.
Kenneth D Laxer +2 more
exaly +2 more sources